ASX Announcements

Neuren corporate presentation, 24 February 2021
Neuren approaching transforming milestones in 2021
Preliminary Final Report and 2020 full year accounts
Change of Director's Interest Notice
Notification of investor briefing webinar
Neuren adds Prader-Willi syndrome to NNZ-2591 pipeline
Successful Phase 1 trial for Neuren's NNZ-2591
Quarterly report and cash flow statement for Q4 2020
European Commission grants 3 NNZ-2591 Orphan designations
Notification of investor briefing webinar